Sign up to save your data!
Some tips to help get started:
Processing...
There are 746 active trials for advanced/metastatic other solid tumor. Click on a trial to see more information. Note that this list also includes some trials that are only for specific cancer types like lung cancer. To see trials customized to a patient, please select a patient above.
746 trials meet filter criteria.
Sort by:
HealthScout AI summary: This trial enrolls adults with advanced solid tumors harboring specific mutations in the KRAS-MAPK pathway (including KRAS, SOS1, PTPN11, class III BRAF, EGFR, and NF1); patients receive either MRTX0902 (a selective SOS1 inhibitor disrupting KRAS activation) as monotherapy or, for those with KRAS G12C mutations, in combination with the KRAS G12C inhibitor adagrasib. Eligible patients must have measurable or evaluable disease, ECOG 0-1, and adequate organ function.
ClinicalTrials.gov ID: NCT05578092
HealthScout AI summary: Eligible patients are adults with locally advanced or metastatic NSCLC harboring EGFR ex19del or L858R mutations who have developed C797X-mediated resistance after prior third-generation EGFR TKI (e.g., osimertinib) therapy; participants receive STX-241, an oral, CNS-penetrant, fourth-generation EGFR inhibitor specifically designed to overcome C797X resistance.
ClinicalTrials.gov ID: NCT06567015
HealthScout AI summary: This trial enrolls adults with advanced or metastatic ER+ HER2- breast cancer, mCRPC, or NSCLC who have progressed after standard therapies, to receive OP-3136, an oral selective KAT6A/B inhibitor targeting key epigenetic regulators, as monotherapy. Eligible patients must have unresectable disease or no further effective standard treatment options.
ClinicalTrials.gov ID: NCT06784193
HealthScout AI summary: This trial enrolls adults with advanced, unresectable or metastatic ovarian, non-small cell lung, pancreatic, endometrial, colorectal cancer, or mesothelioma who have progressed after standard therapies, to receive monotherapy with SGN-MesoC2, an investigational antibody-drug conjugate targeting mesothelin and delivering a novel topoisomerase 1 inhibitor. Eligibility requires measurable disease and good performance status (ECOG 0-1), with some additional criteria for select tumor types.
ClinicalTrials.gov ID: NCT06466187
HealthScout AI summary: Eligible patients are adults with metastatic or unresectable advanced solid tumors—including ovarian, endometrial, triple-negative breast, and non-small cell lung cancers—who have received prior systemic therapy. The investigational treatment is GEN1107, an intravenous antibody-drug conjugate targeting PTK7, which delivers a cytotoxic payload to PTK7-expressing tumor cells.
ClinicalTrials.gov ID: NCT06171789
HealthScout AI summary: Adults with advanced or metastatic mesothelin-expressing cancers (including ovarian cancer and NSCLC) who have progressed after standard therapies or have no suitable standard treatment receive ZW171, a bispecific antibody targeting mesothelin on tumor cells and CD3 on T cells to promote T cell-mediated cytotoxicity.
ClinicalTrials.gov ID: NCT06523803
HealthScout AI summary: This trial enrolls adults with unresectable, locally advanced or metastatic solid tumors—including a wide range such as head and neck, lung, bladder, prostate, breast, colorectal, and others—who have progressed on or are intolerant to standard therapies. Patients receive MGC026, a B7-H3-targeted antibody-drug conjugate delivering a topoisomerase I inhibitor (exatecan), with cohorts in both dose escalation and expansion phases.
ClinicalTrials.gov ID: NCT06242470
HealthScout AI summary: Eligible adult patients with advanced or metastatic solid tumors (including dedicated cohorts for TNBC and melanoma) whose disease is refractory or progressed after standard therapy may receive intratumoral STX-001, a self-replicating mRNA encoding IL-12, as monotherapy or combined with pembrolizumab. Enrollment requires an accessible lesion for injection/biopsy and ECOG 0-1.
ClinicalTrials.gov ID: NCT06249048
HealthScout AI summary: This study enrolls adults with unresectable, locally advanced, or metastatic antigen-rich solid tumors—including TMB-H, MSI-H/dMMR, virally associated, metastatic colorectal, triple negative breast, platinum-resistant ovarian, metastatic castration-resistant prostate, and NSCLC—who lack standard treatment options. Patients receive STAR0602 (invikafusp alfa), a bifunctional bispecific antibody that selectively activates and expands Vβ6/Vβ10 T cell subsets to enhance antitumor immunity.
ClinicalTrials.gov ID: NCT05592626
HealthScout AI summary: This trial enrolls adults with advanced or metastatic colorectal, pancreatic, gastric/gastroesophageal junction, or lung cancers that have progressed after standard therapy, testing PF-08046050 (SGN-CEACAM5C), an anti-CEACAM5 antibody-drug conjugate linked to a topoisomerase I inhibitor, as monotherapy and in combination with bevacizumab. Eligible patients must have measurable disease and ECOG 0-1.
ClinicalTrials.gov ID: NCT06131840
